By: Amber Tong
Bristol Myers Squibb has backed out of a TIGIT partnership with Agenus, returning a bispecific that it had paid $200 million upfront to license. …
Amber Tong is a Senior Editor for Endpoints News, a leading publication covering the biopharmaceutical industry. With a focus on life sciences, Amber's work includes in-depth articles on drug development, clinical trials, biotech financing, and industry trends. Her expertise and contributions have also been featured in NXTmine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Amber's coverage mainly focuses on healthcare and pharmaceuticals, with a significant emphasis on company announcements and clinical trial outcomes. She appears to be particularly interested in developments within the pharmaceutical industry, including drug development, clinical trials, and company acquisitions.
Given her focus on private sector announcements and press releases, Amber may be more responsive to pitches related to exclusive news from within the pharmaceutical industry or expert insights into major developments such as clinical trial results or company strategies.
It is important to note that Amber does not seem to have a specific geographic focus but rather provides comprehensive coverage of global pharmaceutical industry developments.
This information evolves through artificial intelligence and human feedback. Improve this profile .